Advertisement
Product › Details
XRpro® technology
Next higher product group | X-ray fluorescence technology (XRF) | |
Status | 2017-03-28 sales existent | |
Organisation | Icagen Inc. [new, since 0/15] | |
Icagen, Inc.. (3/28/17). "Press Release: Icagen Announces Collaboration with Bayer to Develop Novel XRpro Assays". Durham, NC.
Today the Target-to-Lead company Icagen announces a collaboration with Bayer to develop new X-ray fluorescence assays using the proprietary XRpro® platform. These assays are designed to help Bayer to progress various early discovery programs in the area of transporter targets.
A major obstacle for validation of transporters as targets and subsequent identification of molecules targeting transporters has been the lack of a broadly applicable high-throughput screening platform, especially for non-electrogenic transporters. To date, screening of non-electrogenic transporters in HTS mode can still be challenging and in certain cases is only achieved with indirect readouts. The XRpro® technology employs X-ray fluorescence as a method that enables a high throughput assessment of electrogenic and nonelectrogenic transporters, and is particularly well suited for certain classes of inorganic transporters.
"Icagen looks forward to collaborating with Bayer on this ground-breaking project," said Dr. Doug Krafte, Icagen's CSO. "XRpro represents a unique application of X-ray fluorescence technology and has the potential to unlock new drug discovery e?orts for previously untouched molecular targets."
The project has established key milestones and has the potential to span two years.
About XRpro
The XRpro® technology leverages the unique capabilities of X-ray fluorescence for high throughput analysis of plasma membrane ion channels and transporters, including non-electrogenic symporters and antiporters. XRpro® is a label-free technology that directly quantifies ion flux in cell populations without dyes, fluorophores, and radiolabels and o?ers the ability to conduct assays in complex bu?ers and media, including 100% serum. Biological elements with an atomic number of 16 (sulfur) or greater are measured simultaneously, including biologically important monovalent ions (e.g. K+), divalent ions (e.g. Ca2+), transition metals (e.g. Zn2+), halogens (e.g. Cl-), and tracer ions (e.g., Rb+, Sr2+).
About Icagen
Icagen partners with global pharmaceutical and biotech companies to generate high-quality, advanced leads. As a focused, Target-to- Lead (T2L) company, Icagen works with collaborators in multi-year, integrated drug discovery programs as well as piecemeal projects to fill-in the gaps for R&D e?orts. Born from a biotech background and matured by pharma companies, Icagen brings to partners a North American team with over 20 years of experience in early discovery. The process of drug discovery starts with druggable targets.
Icagen scientists have vast experience in target-based drug discovery, including ion channels, kinases, GPCR's and transporters. The Icagen team works with collaborators to determine target feasibility using state-of-the-art computational chemistry methods. Once a target is selected, the team combines virtual screening, ultra-high throughput screening (uHTS), biology and medicinal chemistry to generate viable leads in an iterative process. For more information email info@icagen.com.
Record changed: 2023-07-10 |
Advertisement
More documents for X-ray technology
- [1] Spectro Analytical Instruments GmbH. (1/4/22). "Press Release: Change in Spectro Management – Michael Privik Succeeds Dr. Christoph Mätzig". Kleve....
- [2] Quantum Analytics. (10/16/18). "Press Release: New Distribution Agreement with Bruker AXS". Foster City, CA....
- [3] Bruker Corporation. (12/19/17). "Press Release: Bruker Celebrated the 100th Customer of Its Newly Introduced Tracer 5i Handheld XRF Elemental Analyzer Optimized for Advanced Applications and Research at Pennsylvania State University". Kennewick, WA....
- [4] Bruker Corporation. (12/13/17). "Press Release: Bruker and The Metropolitan Museum of Art Announce Partnership in the Field of Cultural Heritage Science". New York, NY & Billerica, MA....
- [5] Bruker Corporation. (9/6/17). "Press Release: Bruker Announces the New D8 Discover Plus XRD System". Chiba....
- [6] Bruker Corporation. (8/22/17). "Press Release: Bruker and Dectris Announce Advances in D8 X-ray Diffraction Systems with the New Eiger2 R 500K Detector". Hyderabad....
- [7] Varex Imaging Corporation. (5/1/17). "Press Release: Varex Imaging Completes Acquisition of PerkinElmer's Medical Imaging Business". Salt Lake City, UT....
- [8] Bruker Corporation. (3/3/17). "Press Release: Alcami Invests in Bruker’s D8 Discover HTS System for High-Throughput X-Ray Diffraction Screening in Pharmaceutical Formulation Development". Weert & Karlsruhe....
- [9] Varex Imaging Corporation. (2/13/17). "Press Release: Varex Imaging to Participate in Two Upcoming Investor Conferences". Salt Lake City, UT....
- [10] Varex Imaging Corporation. (1/30/17). "Press Release: Varex Imaging Completes Separation from Varian Medical Systems, Lists on the Nasdaq Stock Market". Salt Lake City, UT....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top